• Gramine as a Precision Ferroptosis Inducer in Cancer Biology

  2026-05-12

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) uniquely enables targeted ferroptosis studies in triple-negative breast cancer through CUL3-mediated MTDH ubiquitination. This article delivers actionable experimental workflows, troubleshooting insights, and comparative advantages for translational cancer biology research using APExBIO’s high-purity Gramine.

• MK 0893: Glucagon Receptor Antagonist for Type 2 Diabetes Re

  2026-05-12

  MK 0893 is an advanced glucagon receptor antagonist enabling reproducible inhibition of cAMP production and glucose excursion reduction in hGCGR mouse models. With nanomolar efficacy and robust selectivity, it streamlines both in vitro and in vivo protocols for metabolic disease research.

• Polymyxin B Sulfate: A Cornerstone for CREC and Resistance M

  2026-05-11

  Explore how Polymyxin B sulfate empowers advanced research on carbapenem-resistant Enterobacter cloacae (CREC) and multidrug-resistant infections. This article uniquely connects molecular action, resistance transmission, and practical assay choices for Gram-negative bacterial infection studies.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-05-11

  This study demonstrates that inhibiting ATM kinase in high grade serous ovarian cancer (HGSOC) cells synergizes with the metabolic modulator fenofibrate, inducing senescence and revealing a vulnerability in HR-proficient tumors. The findings suggest that combining DNA damage response inhibitors with metabolic interventions may expand therapeutic options for patients who do not benefit from conventional HR-targeted therapies.

• Fluorescent DNA Dyes Drive Next-Gen Cell Viability Analysis

  2026-05-10

  Explore how AO/PI Staining Solution advances live/dead cell discrimination using dual fluorescent DNA dyes, enabling translational researchers to achieve high-precision viability assessment in complex samples. This article bridges mechanistic insights, translational relevance, and strategic guidance for integrating fluorescence-based cell counting into cutting-edge workflows, with critical commentary on the latest evidence and best practices.

• ATRA Reverses Platinum-Induced PARP Inhibitor Resistance in

  2026-05-09

  This study demonstrates that all-trans retinoic acid (ATRA) can resensitize epithelial ovarian cancer (EOC) cells to PARP inhibition after cisplatin-induced resistance. By elucidating mechanisms involving NAD+ metabolism and gene expression changes, the research suggests new avenues for overcoming acquired resistance in EOC maintenance therapy.

• ATM Inhibition Promotes Cancer Cell Survival via Macropinocy

  2026-05-08

  This study uncovers how ATM kinase inhibition induces macropinocytosis, supporting cancer cell survival under nutrient scarcity. The findings reveal a metabolic vulnerability in ATM-inhibited tumors and suggest combinatorial strategies targeting nutrient uptake and DNA damage response.

• Cefoperazone Sodium Salt: Optimizing Antibacterial Assays

  2026-05-08

  Cefoperazone (sodium salt) delivers robust, β-lactamase-stable activity for researchers tackling gram-negative resistance. This guide unpacks experimental workflows, troubleshooting, and comparative insights to maximize reliability in advanced antimicrobial assays.

• Workflow Guide: HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-05-07

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables reliable synthesis of Cy3-labeled RNA probes for sensitive fluorescence-based detection, addressing research needs in in situ hybridization and Northern blotting. It is optimized for research use only and should not be applied in diagnostic or clinical workflows.

• Esflurbiprofen: Rapid Antidepressant Action via SERT-nNOS Di

  2026-05-07

  This study pioneers a mechanistically distinct strategy for rapid antidepressant action by demonstrating that esflurbiprofen disrupts the SERT-nNOS complex in the dorsal raphe nucleus. The findings reveal a promising alternative to conventional SSRI therapy, potentially addressing the longstanding delay in antidepressant onset.

• α-Amanitin for Transcriptional Regulation: Protocols & Pitfa

  2026-05-06

  Unlock unmatched precision in transcriptional regulation research with α-Amanitin, the gold-standard RNA polymerase II inhibitor. Discover practical workflows, advanced applications, and expert troubleshooting tips, including insights from the latest studies on chromatin reorganization and oocyte development.

• BMN 673 (Talazoparib): Precision PARP Inhibition in HR-Defic

  2026-05-06

  BMN 673 (Talazoparib) sets a new benchmark for selective PARP inhibition, enabling robust targeting of homologous recombination-deficient cancers through potent PARP-DNA complex trapping. This guide maps advanced workflows, troubleshooting strategies, and actionable protocol parameters for maximizing experimental success.

• Bleomycin Sulfate (A8331): Technical Guide for Controlled DN

  2026-05-05

  Bleomycin Sulfate (A8331) provides a reliable means for researchers to induce DNA strand breaks, model chemotherapy-induced injury, and study pulmonary fibrosis in controlled cell and animal systems. This compound is not suitable for ethanol-based protocols or for applications requiring long-term solution storage due to stability constraints.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual

  2026-05-05

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) offers unmatched dual-fluorescence tracking and immune-evasive design for next-generation gene delivery and translation efficiency assays. This article unpacks stepwise protocols, advanced use-cases, and troubleshooting insights to maximize transfection fidelity and data interpretability in both in vitro and in vivo settings.

• CPI-613: Targeting Tumor Mitochondrial Metabolism in Cancer

  2026-05-04

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) is a first-in-class mitochondrial metabolism inhibitor that disrupts tumor cell energy pathways by targeting PDH and KGDH. It demonstrates dose-dependent apoptosis induction, synergy with chemotherapeutics, and enhances immune sensitivity in resistant cancers. APExBIO supplies CPI-613 for research use, enabling advanced tumor metabolism and apoptosis assays.

11422 records 1/762 page Next 12345 下5页 Last page